Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, announces the release of GastroPlus Version 6.1, the latest version of its state-of-the-art software used by pharmaceutical research scientists for simulation of oral absorption, intravenous dosing, pharmacokinetics, and pharmacodynamics.
Dr. Viera Lukacova, team leader for Simulations Plus’ Simulation Technologies, said: “This new version of GastroPlus incorporates both new types of analysis as well as numerous user convenience features suggested by our worldwide user community. The simulation capability has been expanded to include dosing to the oral cavity via lingual (top of the tongue), sublingual (under the tongue), and buccal (inside the cheek) routes of administration. As a result of suggestions from our users, we’ve also added a long list of convenience features that help both new and experienced users to avoid common mistakes, to provide flexible units for various input data, and to extend the output options in both graphics and text formats. Additionally, we’ve added a major improvement that affects certain low-solubility drugs by incorporating the distribution of bile salts in the intestinal tract for both fasted and fed conditions, and we’ve added the ability to estimate the improved solubility from nanoparticle formulations. Both of these solubility-related improvements provide dramatically better prediction of the dissolution rate and subsequent absorption of drugs that fall into these categories.”
Dr. Lukacova continued, “Now that we’ve released 6.1, we’re hard at work on Version 7.0, which we’ll release early next year. That version will include a comprehensive drug-drug interaction capability as well as the ocular and nasal/pulmonary administration routes we’ve been developing under our funded collaborations with two top-five pharmaceutical companies.”